Kornimate/medical-research-clean huggingface dataset:
cytisine for smoking cessation

Conditions: Tobacco Use Disorder; Alcohol Use Disorder; Smoking Cessation

Summary: the goal of this clinical trial is to evaluate the safety and effectiveness of cytisine as a smoking cessation treatment in individuals with concurrent alcohol use disorder.


Eligibility criteria:
inclusion criteria: * aged 18-65 years; * have tud assessed by structured clinical interview for dsm-5; * have past year aud (active) assessed by structured clinical interview for dsm-5; * report daily cigarette consumption in past month and expired carbon monoxide (co) measurement ≥10ppm at screening; * have fagerstrom test of nicotine dependence (ftnd55) score ≥4; * have motivation to quit within 30 days i.e. contemplation ladder56 score ≥7; * be willing and able to comply with all study procedural and assessment demands; * be able to provide voluntary written informed consent. exclusion criteria: * report prolonged smoking abstinence in the past month preceding screening; * be using other smoking cessation aids * enrolled in another smoking cessation program * be pregnant, breastfeeding, or intending to become pregnant or breastfeed; * exhibit suicidal thoughts or behavior in the past month; * enrolled in another study which would interfere with study procedures or represent a potential risk to the participant * have a serious unstable psychiatric or medical condition preventing participation in the trial. this includes some forms of schizophrenia, ischemic heart disease, heart failure, arterial hypertension (systolic bp above 150; diastolic bp above 100), cerebrovascular diseases, occlusion of blood vessels, kidney and/or liver disease, hyperthyroidism, ulcer, diabetes, chromaffin tumours of the adrenal medulla, and gastroesophageal reflux disease (gerd)
an implant for hearing loss due to removal of neurofibromatosis 2 tumors

Conditions: Neurofibromatosis 2

Summary: this is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (pabi) in patients with neurofibromatosis type 2.

neurofibromatosis type 2 (nf2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. surgical resection of these tumors generally results in the transection of the viiith nerve, destruction of the cochlea and auditory nerve, and total hearing loss. due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. the auditory brainstem implant (abi) provides the only available intervention to restore some auditory sensation to these patients. an abi is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus. the pabi may be placed surgically during tumor resection. efficacy will be assessed using psychophysical and standard speech reception measures.

Eligibility criteria:
inclusion criteria: * diagnosis of neurofibromatosis type 2 * speak english as a primary language exclusion criteria: * physical, psychological, or medical conditions that contraindicate the surgical procedure

Keywords: electric stimulation implants, artificial brainstem electrodes speech perception
study of gefitinib compared with pemetrexed/cisplatin in advanced non-small cell lung cancer patients

Conditions: Toxicity; Non-small Cell Lung Cancer

Summary: the purpose of this study is to examine the efficacy and safety of gefitinib combinated with pemetrexed/cisplatin in advanced non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * patients who were diagnosed by the histologic, cytologic diagnosis of iv non-small cell lung cancer * age from 18 to 70 years old * at least one target lesion diameter spiral ct ≥ 1 cm, or the common ct ≥ 2 cm, and can be measured by imaging tools * ecog 0-1 * expected life time longer than 12 weeks * normal laboratory values: leucocyte≥ 4×109/l neutrophil≥ 1.5×109/l platelet≥100×109/l hemoglobin≥ 10g/l alt and ast ≤2.5×uln (≤5×uln if liver metastasis) exclusion criteria: * patients have not used drugs according to protocol * patients were allergic to pemetrexed or cisplatin * patients received radiotherapy or other biological treatment 4 weeks before the trial * uncontrolled hydrothorax or hydropericardium * neuropathy toxicity ≥ ctc 3 * severe symptomatic heart disease * active upper gastrointestinal ulcer or digestive disfunction * severe infection or metabolic disfunction * patients with other malignant tumor * uncontrolled brain metastases * patients have accepted other clinical trials * female patients during their pregnant and lactation period, or patients without contraception

Keywords: objective response rate time to progression quality of live
expression profiling of microrna following administration of dexmedetomidine

Conditions: Coronary Disease

Summary: the purpose of the study is to find out the differential expression profiling of microrna before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microrna.

background and objective: the use of dexmedetomidine may have benefits on the clinical outcomes of cardiac surgery. micrornas are non-coding rna sequences that act as regulators of gene expression. investigators conduct a study to determine the role of micrornas in cardioprotection mediated by dexmedetomidine. methods: in this study 3 patients were selected. the blood sample were taken before administration of dexmedetomidine.investigators infused loading dose of dexmedetomidine for 10 minutes and maintaining dese of dexmedetomidine for 20 minutes.thirty minutes after the administration, another blood samples were taken and stored in the liquid nitrogen and both the samples were marked. those sample were analyzed for differentially expressed microrna with exiqon mirna array.

Eligibility criteria:
inclusion criteria: * the patients without arrithmia will undergo procedure. exclusion criteria: * the patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.
circulating tumor dna longitudinal monitoring in stage iii-iv lung cancer patients

Conditions: Carcinoma; Non-small Cell Lung Cancer; Lung Neoplasm

Summary: conduct a prospective study in multicenter to confirm the value of circulating tumor dna in longitudinal monitoring of stage iii-iv lung cancer patients.

the study consists of two phases, the first stage is the exploratory stage of blood collection point which is the appropriate effective time after chemotherapy, radiotherapy, targeted therapy. the second phase, which is the expansion of the first phase, is to determine the precise leading time of ctdna relative to tumor biomarkers or image evaluation in determining the efficacy of advanced nsclc cancer therapy. both stages were divided into three subgroups: the chemotherapy group, the radiotherapy group, and the targeted therapy group.

Eligibility criteria:
inclusion criteria: 1. greater than 18 years old; 2. patients with stage iii-iv nsclc; 3. have the tissue specimens (fresh or wax blocks) before this treatment; 4. ps\<=2 in radiotherapy/ chemotherapy group; ps\<=3 in targeted therapy group 5. signing informed consent; exclusion criteria: 1. multiple primary lung cancer; 2. incorporating any unstable systemic disease; 3. histology is not nsclc; 4. unqualified blood samples; 5. patients lacking any one of the detection points.

Keywords: circulating tumor dna lung cancer surveillance longitudinal monitoring lead time
remotely delivered yoga program for chronic low back pain

Conditions: Low Back Pain

Summary: the purpose of this research is to integrate the meditative components of integrative restoration (irest) yoga nidra with simple and safe movement sequences derived from established yoga postures and physical therapy interventions for chronic nonspecific low back pain and to use telemedicine technology to facilitate the intervention in a diverse socioeconomic and racial/ethnic population. this project will first systematically adapt the irest yoga intervention for the incorporation of movement using a consultative and iterative process followed by a pilot intervention to assess the acceptability and preliminary efficacy of this program for pain, back related function and to address body-mind regulation and biopsychosocial-spiritual well-being. hypothesis: a yoga intervention emphasizing meditative movement and relaxation will be safe for remote delivery and effective for biopsychosocial-spiritual outcomes for people with chronic low back pain.


Eligibility criteria:
inclusion criteria: * adults age 18-64 years who report chronic nonspecific low back pain, defined as low back pain of unknown etiology persisting for at least 12 weeks, * participants must report an average pain intensity in the previous week of 4 or greater on an 11-point (0 to 10) numerical rating scale, * demonstrate medium to high risk on the start back screening tool, * understand english * have access to technology including a computer and internet access exclusion criteria: * specific causes of low back pain (e.g. spinal fractures, cancer-related pain) * severe or progressive neurological deficits * severe chronic medical and/or psychiatric comorbidities that may prevent safe participation in the study * established pregnancy * current yoga practice or regular yoga class attendance in the last three months; * current application for a receipt of workers compensation * lack of access to technology including a computer and the internet

Keywords: chronic pain yoga meditation
integration of remote monitoring in the management of chronic immunosuppressive therapy

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis; Spondyloarthritis, Axial; Ankylosing Spondylitis

Summary: systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients. the drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. as a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient. the therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. the initial period is also when side effects most often appear. the aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.


Eligibility criteria:
inclusion criteria: any patient with one of the following conditions * rheumatoid arthritis * psoriatic arthritis * spondyloarthritis * ankylosing spondylitis * systemic sclerosis * systemic lupus erythematosus * sjogren's disease who are prescribed a new immunosuppressive medication for the treatment of their disease among the following: * methotrexate * sulfasalazine * leflunomide * mycophenolate mofetil * azathioprine * cyclosporine a * tacrolimus * tnf inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol) * il6 inhibitors (tocilizumab) * il-17 inhibitors (secukinumab, ixekizumab) * il-23 inhibitors (ustekinumab, guselkumab, risankizumab) * jak-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) * belimumab * anifrolumab exclusion criteria: * treatment with a medication not approved for the condition * inability to use a device for remote call, not even with the help of a caregiver

Keywords: immunosuppression quality of life
conservative pulp therapy of primary molars using theracal

Conditions: Reversible Pulpitis

Summary: the study is a clinical trial that assesses the clinical and radiographic success rates of 3 conservative pulp therapy treatments in primary molars compared to conventional pulpotomy using a bioactive dual cured calcium silicate cement (theracal pt).

participating children will be recruited from the outpatient's clinic of pediatric dentistry department , faculty of dentistry ain shams university and will be allocated to one of the following groups; indirect pulp capping, direct pulp capping, partial pulpotomy or pulpotomy. theracal pt, a dual cured tricalcium silicate cement will be used in all groups as the pulp capping material. children will be followed every 6 months for a period of 1 year to evaluate clinical and radiographic success.

Eligibility criteria:
inclusion criteria: * four to six years old healthy children * cooperative (frankle scale + and ++) * with at least one vital and restorable primary molar with deep caries. exclusion criteria: * history of spontaneous pain, swelling, or sinus tract * pathological mobility * pain on percussion * furcation or periapical radiolucency * internal or external pathological root resorption * widening of periodontal membrane space * discontinuity of lamina dura.

Keywords: indirect pulp capping direct pulp capping partial pulpotomy pulpotomy theracal primary molars
compare elbow mnt-bbavf with wrist rcavf for hemodialysis access

Conditions: End Stage Renal Disease on Dialysis

Summary: investigator plan to conduct a multicenter, open-labelled, randomized study to compare the primary patency and safety of elbow mnt-bbavf and wrist rcavf in hemodialysis patients.

although wrist radiocephalic arteriovenous fistula (rcavf) has been recommended as first preferred fistula in many clinical practical guidelines for vascular access, there are no randomized controlled trials (rcts) comparing the recommended anatomic order of distal-to-proximal access construction up to now. a modified non-transposed brachiobasilic arteriovenous fistula (mnt-bbavf) that has a long length of suitable superficial vein for cannulation and a sufficient blood flow for effective dialysis has been introduced by investigator for several years. in addition, mnt-bbavf has good primary patency and a low risk of complication and leave opportunities for further procedures in the event of failure. investigator plan to conduct a multicenter, open-labelled, randomized study to compare the primary patency and safety of elbow mnt-bbavf and wrist rcavf in hemodialysis patients.

Eligibility criteria:
inclusion criteria: 1. patients with chronic kidney disease (ckd) stage 5 requiring hemodialysis (including pre-dialysis patients) and eligible for a native arteriovenous fistula; 2. adult (age ≥ 18 years old); 3. preoperative doppler ultrasonography showing target vein diameter(s) ≥ 2.0 mm and target artery diameter(s) ≥ 2.0 mm; 4. estimated life expectancy \> 1 year; 5. written informed consent obtained; 6. patient is free of clinically significant conditions or illness that may compromise the procedure within 30 days prior to avf creation exclusion criteria: 1. patients with a history of cerebral hemorrhage or gastrointestinal hemorrhage are excluded from the study; 2. new york heart association class iii or iv heart failure; 3. patients who are absent of median cubital vein and verified by preoperative doppler ultrasonography are excluded from the study; 4. known central venous stenosis, central vein narrowing \> 50% or deep vein thrombosis based on imaging on the same side as the planned avf creation; 5. prior arm surgically created access in the planned treatment arm; 6. immunosuppression (i.e. use of immunosuppressive medications to treat an active condition).
nursing intervention in weight and metabolic syndrome management in first-episode psychosis (metakop)

Conditions: First Episode Psychosis (FEP); Metabolic Syndrome X

Summary: the goal of this clinical trial is to evaluate if a nursing intervention based on the carbohydrate-insulin model can effectively reduce weight and manage the risk of metabolic syndrome (mets) in individuals with first-episode psychosis. the main questions it aims to answer are: will the intervention lead to a clinically significant weight loss (≥5%)? can the intervention improve metabolic parameters, psychopathological state, physical activity level, and quality of life? researchers will compare participants receiving the specialized nursing consultations to those receiving routine care to see if the former group experiences greater improvements in weight loss and metabolic risk reduction. participants will: attend a series of 8 nursing consultations focused on dietary habits based on the carbohydrate-insulin model and physical activity. complete assessments at the start, 6 months, and 12 months, including weight, metabolic parameters, and psychological evaluations.


Eligibility criteria:
inclusion criteria: 1. patients admitted to the early intervention program (eip). 2. first-episode psychosis (fep) within the last 5 years. 3. diagnosis of psychosis from the f2 spectrum or an affective disorder with psychotic symptoms according to icd-10. exclusion criteria: 1. cognitive inability to learn or comorbid intellectual disability that interferes with study procedures. 2. comorbid diagnosis of neurological pathology. 3. language or comprehension impairments preventing accurate data collection. 4. use of hypoglycemic medication before or during the study. 5. refusal to participate

Keywords: fep psychosis metabolic syndrome nursing mental health nurse
study to assess the effectiveness of existing anti vascular endothelial growth factor (anti vegf) in patients with wet age-related macular degeneration (wamd) (aura)

Conditions: Ophthalmology, Macular Degeneration

Summary: retrospective, non-interventional, observational multi-center field study. patients diagnosed with wet age-related macular degeneration (wamd) and having started treatment with ranibizumab between january 1, 2009 and august 31, 2009 must be consecutively screened and, if eligible, enrolled. patients will be followed up at maximum until august 31, 2011. switch to any other anti vascular endothelial growth factor (anti vegf) treatment will be documented and followed up. for each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.


Eligibility criteria:
inclusion criteria: * diagnosis of wet age-related macular degeneration * start of anti vascular endothelial growth factor (anti vegf) therapy with ranibizumab between january 1, 2009 and august 31, 2009 * informed consent form signed, where required exclusion criteria: * participation in an investigational study during anti-vegf therapy (from start up to august 31, 2011) that involved treatment with any drug or medical device

Keywords: retrospective studies
cerebrolysin in sah (subarachnoidal haemorrhage) - observational study

Conditions: SAH (Subarachnoid Hemorrhage)

Summary: subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. in recent years, advances in surgical techniques have im-proved the mortality rate. however, there is still need for the research for the optimal possible final effect of treatment. in our study, we've decided to examine the effect of a multimodal approach including cerebrolysin in the supportive treatment of patients. we've examined the supply of neuroprotective drugs and neuromonitoring.


Eligibility criteria:
inclusion criteria: * age \>18 years old, diagnosis of sah, treatment in icu conditions exclusion criteria: * age \<18 years, medical history of allergy to cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Keywords: sah cerebrolysin neuromonitoring
use of intraoperative clonidine for prevention of postoperative agitation in pedriatic anesthesia with sevoflurane.

Conditions: Is an Only Child

Summary: the purpose of this study is to determine efficacy of intraoperative clonidine to prevent postoperative agitation in pediatric anesthesia with sevoflurane.


Eligibility criteria:
inclusion criteria: * aged 2 - 12 years. * need for tonsillectomy / adenotonsillectomy. * physical status of the american society of anesthesiologists (asa) 1, 2 or 3. * anestesia geral com sevoflurano. * use of intraoperative dipyrone, 30-50mg/kg, iv. exclusion criteria: * changes in consciousness. * neurological deficit. * use of another drug as medication before anesthesia.

Keywords: clonidine psychomotor agitation anesthesia recovery period tonsillectomy child, preschool
a study of tarceva (erlotinib) in first line in patients with locally advanced or metastatic lung adenocarcinoma with egfr mutations

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this open-label, non-randomized, one-arm study will evaluate the safety and efficacy of tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show epidermal growth factor receptor (egfr) activating mutations. patients will receive tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically or cytologically documented, inoperable, locally advanced, recurrent or metastatic (stage iiib or stage iv) lung adenocarcinoma * non-small cell lung cancer with an egfr activating mutation * patients must have evidence of disease, but measurable disease is not mandatory * eastern cooperative oncology group (ecog) performance status 0-2 * adequate renal and liver function exclusion criteria: * prior chemotherapy or other systemic anti-cancer treatment. neoadjuvant/adjuvant chemotherapy is allowed if completed within 6 months prior to enrolment. prior radiochemotherapy is allowed if completed more than 6 months before start of study treatment * prior therapy with systemic anti-tumour therapy with her1/egfr inhibitors * any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin carcinoma * brain metastasis or spinal cord compression not yet definitely treated with surgery and/or radiation * patients unable to take oral medication or requiring intravenous alimentation, with prior surgical procedures affecting absorption or active peptic ulcer disease * any significant ophthalmologic abnormality, especially those likely to increase the risk of corneal epithelial lesions; the use of contact lenses is not recommended during the study * pregnant or breast-feeding women